Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- ERYP
- Price
- -
- Stock movement up
- +0.03 (4.85%)
- Company name
- Erytech Pharma S.A. ADR
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 41.41M
- Ent value
- 24.94M
- Price/Sales
- -
- Price/Book
- 1.76
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- 67.44
- Forward P/E
- -
- PEG
- -
- EPS growth
- -66.92%
- 1 year return
- -33.83%
- 3 year return
- -56.14%
- 5 year return
- -
- 10 year return
- -
Last updated: 2024-12-17
DIVIDENDS
ERYP does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | 67.44 |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | - |
| Price to Book | 1.76 |
| EV to Sales | - |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 60.75M |
| EPS (TTM) | 0.02 |
| FCF per share (TTM) | - |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 0.00 |
| Gross profit (TTM) | 0.00 |
| Operating income (TTM) | -2.80M |
| Net income (TTM) | 614.00K |
| EPS (TTM) | 0.02 |
| EPS (1y forward) | -2.80 |
Margins
Loading...
Margins data
| Gross margin (TTM) | - |
| Operating margin (TTM) | - |
| Profit margin (TTM) | - |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 38.79M |
| Net receivables | 2.53M |
| Total current assets | 42.63M |
| Goodwill | 0.00 |
| Intangible assets | 5.00K |
| Property, plant and equipment | 0.00 |
| Total assets | 45.81M |
| Accounts payable | 1.56M |
| Short/Current long term debt | 13.57M |
| Total current liabilities | 11.68M |
| Total liabilities | 22.32M |
| Shareholder's equity | 23.49M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | 0.00 |
| Capital expenditures (TTM) | 0.00 |
| Free cash flow (TTM) | 0.00 |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | 2.61% |
| Return on Assets | 1.34% |
| Return on Invested Capital | 1.79% |
| Cash Return on Invested Capital | - |
STOCK INFORMATION
Downside potential
Loading...
Downside potential data
| ERYP | S&P500 | |
| Current price drop from All-time high | -97.89% | -4.66% |
| Highest price drop | -98.98% | -56.47% |
| Date of highest drop | 30 Dec 2022 | 9 Mar 2009 |
| Avg drop from high | -79.50% | -11.07% |
| Avg time to new high | 1242 days | 12 days |
| Max time to new high | 1241 days | 1805 days |
COMPANY DETAILS
Marketcap
41.41M
Marketcap category
Small-cap
Description
PHAXIAM Therapeutics S.A., a biopharmaceutical company, focuses on developing treatments for resistant bacterial infections in France and the United States. It develops eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing erymethionase, a preclinical product candidate that consists of methionine-"-lyase in red blood cells to target the amino acid metabolism of cancer cells and induce tumor starvation. The company was formerly known as ERYTECH Pharma S.A. and changed its name to PHAXIAM Therapeutics S.A. in June 2023. PHAXIAM Therapeutics S.A. was incorporated in 2004 and is headquartered in Lyon, France.
Employees
49
Website
Investor relations
-
SEC filings
CEO
Gil Beyen
Country
USA
City
Lyon
Stock type
American depositary share
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
No items found
iO Charts is a Seeking Alpha partner